Navigation Links
Aspirin may Help to Prevent Colon Cancer in High-risk Individuals

A new study has found how medical science could employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.

The study was conducted by a team of researchers led by Sanford Markowitz at the Ireland Cancer Center.

As part of the study, researchers demonstrated the hypothesized mechanism by which the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), also called COX-2 inhibitors, act to decrease the risk of developing colon cancer.

Researchers found that two-thirds of colon cancers have high levels of expression of the COX-2 enzyme, which is blocked by aspirin. Individuals who regularly used aspirin over a course of several years demonstrated a 36 percent decrease in the risk of developing one of these high COX-2 expressing colon cancers. These results again demonstrated that drugs that block COX-2 can decrease the risk of colon cancer, and demonstrated that such drugs specifically target those individuals whose tumor development is encouraged by the action of the COX-2 enzyme.

"The compelling evidence that chronic use of aspirin or certain NSAIDS can substantially lower the risk of colon cancer has important implications, especially because colon cancer is the second leading cause of cancer death, Markowitz wrote.

"Interventional trials have shown a decreased risk of the development of colon cancer in high-risk subjects who were given aspirin or COX-2 selective NSAID inhibitors and observational trials have associated a decreased risk of colon cancer with aspirin use," Markowitz added. br>
"The researchers' findings provide powerful support for the role of COX-2 as a key mediator in the development of colon cancer and now pose questions about the biologic basis and clinical applications of discovering differences that express high or low levels of COX-2, he added.

Earlier research by Markowitz in the field of co lon cancer genetics and prevention found that a new Celebrex-like gene called 15-PGDH suppresses the grown of colon cancer, which may lead to the development of a new drug for colon cancer prevention.

Celebrex is a naturally occurring Cox-2 inhibitor.

The findings of the study were published in May issue of New England Journal of Medicine.


Related medicine news :

1. What happens when Asthmatics consume Aspirin?
2. Aspirin reduces deaths
3. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
4. Aspirin - a drug after one’s own hear
5. Aspirin deflated
6. Aspirin surpasses Modern Anti-clotting Drugs
7. Night Time Aspirin Regimen Found to Reduce Blood Pressure
8. Aspirin Lowers Leukemia Risk
9. Aspirin usage linked with pancreatic cancer
10. Aspirin Found To Reduce The Risk Of Colon Cancer
11. Aspirin Induced Asthma , A Little-Known Inducer
Post Your Comments:

(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- ... of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays ... film for accurate interpretation by the radiologist. The marking utensils are so small, ... Calif., has found a way to alleviate this problem. , He developed the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... ) has announced the addition of ... Testing Market: Campylobacter, Cryptosporidium, E. Coli, ... Yersinia" report to their offering. ... announced the addition of the ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... --  Craneware, Inc ., the healthcare market leader ... company will showcase a new version of its ... at the American Society for Health-System Pharmacists (ASHP) ... features are focused on simplifying and streamlining the ... pharmacy charges to ensure compliance and optimal revenue ...
Breaking Medicine Technology: